Skip to search formSkip to main contentSkip to account menu

Immunooncology

The study of cell surface markers on tumor cells which can be recognized by antibodies, and the development of diagnostic reagents or therapeutic… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Highlights from 11th Breast-Gynecological and Immunooncology International Cancer Conference (BGICC), 17–18 January 2019, Egypt
During the 11th Breast-Gynecological and Immunooncology International Cancer Conference (BGICC), which was held on 17 and 18… 
Review
2018
Review
2018
Immunooncology in Breast Cancer: Active and Passive Vaccination Strategies
Immunotherapies are set to become part of the therapeutic repertoire for breast cancer in the near future. Active vaccination is… 
2018
2018
Applications of Bioinformatics and Systems Biology in Precision Medicine and Immunooncology
Next-Generation Sequencing (NGS) technology, o en seen as the foundation of precisionmedicine, has been successfully applied in… 
2018
2018
Estimating the Long-Term Outcomes Associated With Immuno-Oncology Therapies : Challenges and Approaches for Overall Survival Extrapolations
Cure, parametric mixture and landmark models may provide more insight into the potential mechanism of action of immunooncology… 
2018
2018
Immunotherapy of Breast Cancer
sent the basis for individualized immunotherapies [1–4]. These include the underlying mechanisms of BC cells to evade immune… 
2017
2017
[Recent advances of immunooncology in the treatment of solid tumours and haematological malignancies: the immune checkpoint inhibitors].
Cancer immunotherapy is coming of age, as outstanding results can be achieved in the therapy of cancer with poor prognosis by… 
2017
2017
[The role of immunooncology in the treatment of urothelial cancer].
Data published in November 2016 showed a significant survival benefit for the PD-1 antibody Pembrolizumab in the second-line… 
Review
2017
Review
2017
Changes in numbers of randomized (RCT) versus non-randomized (NRCT) clinical trials from 2004-2016: Evidence of shifting cancer drug development pathway.
2543Background: Trials using randomized designs have been conducted for decades to demonstrate efficacy of novel anti-cancer… 
2016
2016
Compositions and methods for immunooncology
The present invention is directed to genome editing systems, reagents and methods for immunooncology. 
2011
2011
Cancer Immunothearapy More than Vaccines "Psychoneuro-Immunooncology: Cancer, the Host, and the Surgeon"
Cancer immunology is extremely complex with numerous interactions between the tumor and the host. It is time for those that treat… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)